Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | UBE2N | P61088 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861287 | 0.87 | MPO (0.62) | MPOHSD17B10GLAMAPTGAA | |
| SCHEMBL2862963 | 0.87 | MPO (0.54) | MPOHSD17B10GLAMAPTGAA | |
| SCHEMBL2861294 | 0.86 | HSD17B10 (0.47) | MPOHSD17B10GLAMAPTGAA | |
| SCHEMBL2857505 | 0.84 | MPO (0.57) | MPOHSD17B10GLAMAPTGAA | |
| SCHEMBL2858056 | 0.77 | CCR6 (0.53) | MPOHSD17B10GLAMAPTGAA | |
| SCHEMBL2854670 | 0.76 | MPO (0.63) | MPOHSD17B10GLAMAPTGAA | |
| SCHEMBL2859666 | 0.75 | MPO (0.71) | MPOHSD17B10GLAMAPTGAA | |
| SCHEMBL2855786 | 0.75 | MPO (0.53) | MPOHSD17B10GLAMAPTGAA | |
| SCHEMBL2861565 | 0.75 | MPO (0.61) | MPOHSD17B10GLAMAPTGAA | |
| SCHEMBL2867367 | 0.74 | MPO (0.54) | MPOHSD17B10GLAMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290480-B2 | Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same | Shin Poong Pharmaceuticals Co., Ltd. (KR) | 2016-03-22 | — | — | US | claimed |
| US-20130102622-A1 | Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2013-04-25 | — | — | US | claimed |
| US-8404696-B2 | Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2013-03-26 | — | — | US | claimed |
| EP-2239257-B1 | NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME | SHIN POONG PHARMACEUTICAL CO LTD (KR) | 2012-06-06 | — | — | EP | claimed |
| US-20100311769-A1 | NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2010-12-09 | — | — | US | claimed |
| US-9290480-B2 | Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same | Shin Poong Pharmaceuticals Co., Ltd. (KR) | 2016-03-22 | — | — | US | disclosed |
| US-20130102622-A1 | Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2013-04-25 | — | — | US | disclosed |
| US-8404696-B2 | Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2013-03-26 | — | — | US | disclosed |
| EP-2239257-B1 | NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME | SHIN POONG PHARMACEUTICAL CO LTD (KR) | 2012-06-06 | — | — | EP | disclosed |
| US-20100311769-A1 | NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2010-12-09 | — | — | US | disclosed |
| EP-2239257-A2 | NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME | Shin Poong Pharmaceutical Co. Ltd. (KR) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311769-A1 | NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME | AQP4, PMP22, CNTN1 | MPO 1589/4885HSD17B10 2598/4885GLA 2013/4885 |
| US-20130102622-A1 | Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same | AQP4, PMP22, CNTN1 | MPO 1589/4885HSD17B10 2598/4885GLA 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.